Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Fragliasso V, Verma A, Manzotti G, Tameni A, Bareja R, Heavican TB, et al. The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK anaplastic large cell lymphoma by regulating the DNA helicase HELLS. Leukemia. 2020;34(11):2964-2980.

Pisapia DJ, Ohara K, Bareja R, Wilkes DC, Hissong E, Croyle JA, et al. Fusions involving BCOR and CREBBP are rare events in infiltrating glioma. Acta Neuropathol Commun. 2020;8(1):80.

Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, et al. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. Eur Urol. 2020;78(4):637-639.

Nanayakkara J, Tyryshkin K, Yang X, Wong JJ, Vanderbeck K, Ginter PS, et al. Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data mining. NAR Cancer. 2020;2(3):zcaa009.

Hoda SA, Hoda RS. Diagnostic Histopathology of Tumors. Am J Clin Pathol. 2020.

Zhou X, He C, Ren J, Dai C, Stevens SR, Wang Q, et al. Mature myelin maintenance requires Qki to coactivate PPARβ-RXRα-mediated lipid metabolism. J Clin Invest. 2020;130(5):2220-2236.

Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, et al. Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2020;52(10):1132.

Lee C, Huang X, Di Liberto M, Martin P, Chen-Kiang S. Targeting CDK4/6 in mantle cell lymphoma. Ann Lymphoma. 2020;4.

Dalton T, Doubrovina E, Pankov D, Reynolds R, Scholze H, Selvakumar A, et al. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Blood. 2020;135(21):1870-1881.

van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020;4(23):6039-6050.